Notice for vosoritide (BioMarin Pharmaceutical Australia Pty Ltd)
Active ingredients
vosoritide
Date of review outcome
Lapse date
Type
Priority review
Indication
Treatment of achondroplasia in patients less than 2 years of age whose epiphyses are not closed. The diagnosis of achondroplasia should be confirmed by appropriate genetic testing
Therapeutic area
Inherited bone disorder